Preclinical Evaluation of GluR2-3Y Peptide as a Potential New Medication for Poly

描述(由申请人提供)：药物滥用和成瘾在经济和社会成本以及人类个人成本方面对北美社会构成了巨大的消耗。迫切需要有效的药物来治疗成瘾。尽管针对某些类型的成瘾，即阿片成瘾的药物开发取得了进展，但这些药物有明显的缺点。目前仍没有针对甲基苯丙胺或可卡因成瘾等多种成瘾的已获批准的治疗方法。更复杂的情况是，许多吸毒成瘾程度高的边缘人群也有很高的多种药物成瘾，即这些人群中的许多人经常使用多种药物并对多种药物上瘾。由于每种成瘾的潜在机制不同，针对这类个人和人群的治疗策略是复杂的。针对不同类型成瘾的共同机制的创新策略可能在治疗这种多药成瘾方面大有裨益，此外也有助于治疗单药物成瘾。不列颠哥伦比亚大学的研究人员已经开发出一种前景看好的先导化合物，作为一种潜在的成瘾疗法。这种多肽化合物并不直接针对药物受体，而是针对成瘾行为背后的联想和学习机制。这些学习和联想机制已被证明对成瘾的渴望和复发方面都是关键的，而与吸毒的回报方面无关。该研究项目的长期目标是使用先导肽化合物进行人体临床试验，最初的目标人群是注射吸毒者，其中至少有一部分吸毒者对多种物质上瘾。因此，本文提出的短期目标是进行更多的非临床试验，将该项目定位为后续正式的临床前安全性和毒性计划，以便快速推进FDA调查性新药申请和/或加拿大卫生部临床试验申请。研究建议中描述的实验包括在多药成瘾动物模型中进一步测试先导化合物；测定先导化合物的最小有效剂量、最大耐受剂量、治疗指数和最佳剂量；先导化合物在动物模型中的全面药代动力学和生物分布概况；以及研究替代给药方式，鼻腔给药，以潜在扩大使用化合物在更广泛目标人群中的适用性和可行性。

DESCRIPTION (provided by applicant): Substance abuse and addiction represents a huge drain on North American society, in terms of economic and social costs, as well as the human individual cost. The need for effective medications to treat addiction is urgent. Although medications development has progressed for certain types of addiction, namely opioid addiction, these medications have significant drawbacks. There remain no currently approved therapies for many types of addiction such as methamphetamine or cocaine addiction. Further complicating matters is that many marginalized populations suffering from high levels of addiction also have very high levels of polydrug addiction that is, many individuals in these populations regularly use and are addicted to multiple substances. Treatment strategies for such individuals and populations are complex due to the various mechanisms underlying each type of addiction. Innovative strategies that target mechanisms common to different types of addiction may be of great benefit in treating such polydrug addictions, in addition to also be useful for treating single substance addictions. Researchers at The University of British Columbia have developed a promising lead compound as a potential addiction therapy. This peptide compound does not directly target drug receptors, but rather targets the association and learning mechanisms underlying addiction behaviors. These learning and association mechanisms have been shown to be critical for both the craving and the relapse aspects of addiction, and are not related to the reward aspects of drug use. It is a long range goal of the research project to conduct a human clinical trial using the lead peptide compound, with an initial target population of injection drug users where at least a portion of such drug users are addicted to multiple substances. Thus the short term goals proposed herein are to perform additional non-clinical experiments to position the project for a follow-on formal preclinical safety and toxicity program, in order to proceed quickly towards an FDA Investigational New Drug Application and/or Health Canada Clinical Trial Application. The experiments described in the research proposal include further testing of the lead compound in an animal model of polydrug addiction; determination of minimum efficacy dose, maximum tolerated dose, therapeutic index, and optimal dose of the lead compounds; full pharmacokinetic and biodistribution profiling of the lead compound in animal model; and investigation of an alternate mode of delivery, intranasal, to potential expand the applicability and feasibility of using the compound with a broader target population.